China has long advocated for seed source independence ... could bypass natural plant gene inheritance. They aim to deploy a CRISPR-based gene editing system to help the transmission of preferred ...

China has elucidated the latest research trends of CRISPR–Cas13 in RNA-targeted therapies. Prof. Yao says, "By focusing on ...

Two of the first efforts to treat Duchenne muscular dystrophy with CRISPR gene editing are getting off the ground in China, even as projects in the U.S. have seemingly stalled.

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

As U.S. programs to develop treat treatments for Duchenne muscular dystrophy stall, two of the first efforts in China to treat the condition with CRISPR gene editing are taking off.

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

July 30, 2024 — A research group has developed a new method that further improves the existing CRISPR/Cas technologies: it allows a more precise and seamless introduction of tags into proteins ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.